RINVOQ® (Upadacitinib) Receives Its Sixth U.S. FDA Approval

RINVOQ is now approved as the first and only oral JAK inhibitor for adults with active non-radiographic axial spondyloarthritis (nr-axSpA)RINVOQ i...

Related Keywords

Chicago ,Illinois ,United States ,Ohio ,Oregon ,America ,Thomas Hudson ,Cassie Shafer ,Twitter ,Drug Administration ,Rheumatic Diseases At Oregon Health Science University ,Exchange Commission ,Other Health ,Allergan ,Facebook ,Abbvie Inc ,Spondylitis Association Of America ,Rheumatology Clinics For The Division Of Arthritis ,Multichannel News Release ,Atul Deodhar ,Rheumatology Clinics ,Rheumatic Diseases ,Oregon Health ,Science University ,Spondylitis Association ,Spa Signs ,Total Back Pain ,Ankylosing Spondylitis Quality ,Abbvie Assist ,Important Safety Information About ,Medication Guide ,Consumer Brief Summary ,Mississippi River ,Full Prescribing Information ,Allergan Aesthetics ,Private Securities Litigation Reform Act ,Quarterly Reports ,Evaluate Efficacy ,Adult Participants With Axial Spondyloarthritis ,Understanding Axial Spondyloarthritis ,Maintenance Therapy ,Subjects With Moderately ,Severely Active Ulcerative ,Placebo Controlled Study ,Endoscopic Remission ,Severely Active Crohn ,Disease Who Have Inadequately Responded ,Are Intolerant ,Participants With Giant Cell Arteritis ,Study Comparing Upadacitinib ,Participants With Psoriatic Arthritis Who Have ,Inadequate Response ,Compare Safety ,Adult Participants With Moderate ,Severe Atopic Dermatitis ,Subjects With Takayasu Arteritis ,